Investing
Boston Properties to sell interest in two assets valued at about $1.7 billion
© Reuters.
(Reuters) -Real estate investment trust Boston Properties (NYSE:) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion.
Massachusetts, especially Cambridge and Boston, is known to be a hotspot for biotech companies including Moderna (NASDAQ:). The state is also regarded as the top biopharma cluster in the United States.
Norges Bank Investment Management is investing $746.4 million to form the joint ventures to own both properties totaling nearly 810,000 square feet.
Boston Properties, which is the largest publicly traded developer, and manager of premier workplaces, will retain a 55% interest in 290 and 300 Binney Street, and provide development, management and leasing services.
290 Binney Street is under construction and pre-leased to AstraZeneca (NASDAQ:), while 300 Binney Street is under redevelopment and pre-leased to the Broad Institute, a non-profit organization.
Read the full article here
-
Make Money6 days ago
10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money5 days ago
10 Ways to Make Money As a Graphic Designer
-
Personal Finance4 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Investing5 days ago
Could Easier Cancellations Build Customer Loyalty?
-
Investing6 days ago
Airbus keeps top spot with 766 jet deliveries in 2024 By Reuters
-
Investing3 days ago
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles5 days ago
Trump’s 2025 Inaugural Committee Raises Record $170 Million
-
Passive Income6 days ago
How to Build a Solid Go-to-Market Strategy for 2025